Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
ID: 349827Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Aug 10, 2023, 12:00 AM UTC
  4. 4
    Due Sep 7, 2026, 12:00 AM UTC
Description

The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)." This initiative invites applications for the identification and development of small molecules that can elucidate disease biology or serve as therapeutic agents, with a focus on advancing research related to cancer treatment. The program encompasses various stages of discovery research, including assay development, high-throughput screening, hit validation, and optimization of lead compounds, encouraging innovative methodologies to enhance understanding of cancer biology. Interested applicants, including a wide range of institutions and organizations, must submit their proposals by September 7, 2026, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

Point(s) of Contact
Files
Title
Posted
Aug 24, 2024, 2:22 AM UTC
Aug 24, 2024, 2:22 AM UTC
The Department of Health and Human Services, through the National Cancer Institute (NCI), has issued a Notice of Funding Opportunity (NOFO) aimed at advancing research in the discovery and development of novel small molecules for cancer treatment. This initiative, reissuing the funding opportunity PAR-20-271 under NOFO number PAR-23-264, seeks proposals for the development of assays and screening for potential chemical probes or drugs. The eligible applicants include various institutions, nonprofits, and foreign entities, with an emphasis on promoting research related to underrepresented cancer targets and pathways. Key research stages include developing primary screening assays, implementing high-throughput screens, and validating initial hits through comprehensive follow-up assays. The program encourages innovative approaches and robust methodologies to ensure the relevance of compounds in understanding cancer biology and therapeutic strategies. Applications are expected to address specific aspects of assay design, screening implementation, and hit validation while collaborating with experts in medicinal chemistry and screening technologies. The funding will support grants for up to three years, contingent upon the successful application and available NIH appropriations, reflecting a commitment to bolster the fight against cancer through scientific discovery.
Similar Opportunities
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators" through the National Cancer Institute (NCI). This initiative aims to support research focused on the identification and development of small molecules that can elucidate cancer biology and contribute to therapeutic advancements. The funding is intended for various eligible applicants, including educational institutions and non-profit organizations, with a flexible budget and a project duration of up to three years. Key deadlines include an application submission window starting January 5, 2025, and a closing date of September 7, 2026. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-153.html.
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity for Research Project Grants (R01) aimed at the development of screening assays for drug candidates targeting psychiatric disorders. The primary objectives of this initiative are to stimulate research in the discovery and development of novel small molecules that can potentially treat mental illnesses, as well as to validate compounds that demonstrate desired biological activity through rigorous screening processes. This funding is crucial for advancing therapeutic options for conditions such as depression, schizophrenia, and PTSD, and it encourages applicants to align their proposals with the National Institute of Mental Health (NIMH) priorities. Interested applicants must submit their proposals by May 7, 2026, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on the early-stage development of innovative technologies for molecular and cellular analysis in cancer research, with an emphasis on enhancing characterization of cancer biology and addressing health disparities. Eligible applicants include a wide range of organizations, such as higher education institutions, non-profits, and tribal governments, with funding available up to $150,000 annually for a project period not exceeding three years. The total estimated funding for this program is approximately $4.2 million, with about 17 awards expected to be made. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by October 3, 2025.
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on the development and validation of innovative technologies designed to enhance cancer research methodologies, particularly in areas such as diagnostics, treatment, and addressing health disparities. The funding program is part of the National Cancer Institute's (NCI) Innovative Molecular Analysis Technologies (IMAT) Program, with a total estimated funding of $4.3 million available for approximately 10 awards, each capped at $300,000 per year for projects lasting up to three years. Interested applicants must submit their proposals by October 3, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research in drug discovery for psychiatric disorders. The initiative focuses on the development and validation of screening assays to identify effective chemical hits for conditions such as depression, bipolar disorder, and schizophrenia, encouraging innovative approaches in mental health research. This grant opportunity is open to a wide range of eligible applicants, including higher education institutions and community-based organizations, with no budget limits and a maximum project period of five years. Interested parties can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications accepted until May 7, 2026.
Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity for the Discovery and Development of Natural Products for Cancer Interception and Prevention, specifically through a cooperative agreement mechanism. This initiative aims to support the discovery and development of novel, safe, and effective natural products that target cancer prevention, structured in two phases: the UG3 phase for initial screenings and assay development lasting up to three years, followed by the UH3 phase for full-scale evaluations lasting up to two years. The program emphasizes the importance of high-throughput screening strategies and collaboration with existing NCI natural product libraries, with a total funding allocation of $4.5 million for approximately 12 awards. Interested applicants must submit their proposals by June 13, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer," aimed at supporting the validation of molecular, cellular, and imaging markers for cancer detection, diagnosis, and treatment. This initiative encompasses a two-phase cooperative agreement mechanism: the UH2 phase focuses on analytical validation of assays over a two-year period, while the UH3 phase supports clinical validation for up to three years, utilizing well-annotated biospecimens from clinical trials. The program emphasizes the importance of multidisciplinary collaboration to enhance the development of assays that can significantly improve cancer research and patient care. Eligible applicants include various institutions and organizations, with a funding ceiling of $275,000 for the UH2 phase and up to $250,000 per year for the UH3 phase. Applications will be accepted starting January 19, 2024, with a final submission deadline of October 15, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer" through a cooperative agreement mechanism (UH2/UH3). This initiative aims to support the validation of molecular, cellular, and imaging biomarkers essential for cancer detection, diagnosis, prognosis, and treatment response monitoring, with a focus on both analytical and clinical validation phases. The funding is intended for projects that demonstrate a working assay on human samples and justify its clinical relevance, fostering multi-disciplinary collaborations among scientific investigators, oncologists, and clinical laboratory scientists. Interested applicants should note that the application deadline is October 14, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-074.html.
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer," aimed at enhancing the validation and adoption of biomarkers and assays critical for cancer detection, diagnosis, and treatment response prediction. This initiative seeks projects that utilize established assays with demonstrated analytical validation for clinical use, fostering collaboration among scientific experts to address significant gaps in cancer research. The funding amount is capped at $250,000 per year for a project duration of up to three years, with applications due by October 14, 2026. Interested applicants can find more information and application details at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov.